"The Effect of The Combination Therapy of Statin and SGLT2i in The Treatment of Ischemic Heart Disease"

NCT06520891 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2025-09-11

No results posted yet for this study

Summary

correlate the serum level of statin and SGLT2i when given as polytherapy with HPLC in ischemic heart failure patients and their laboratory tests (cholesterol, LDL, HDL and TG...)

Conditions

  • 2 Drugs Are Statin and SGLT2i

Interventions

DRUG

Statin and SGLT2i

Statin as atrovastatin SGLT2i as dapagliflozin

Sponsors & Collaborators

  • Fayoum University

    lead OTHER

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2025-11-30
Completion
2025-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06520891 on ClinicalTrials.gov